Over 50% cancer bears TP53 mutation, the highly stabilized mutant p53 protein drives the
tumorigenesis and progression. Mutation of p53 not only cause loss-of-function and …

Nuclear receptor binding SET domain proteins (NSDs) catalyze the mono-or dimethylation
of histone 3 lysine 36 (H3K36me1 and H3K36me2), using S-adenosyl-l-methionine (SAM) …

Regulated induced proximity targeting chimeras (RIPTACs), a new class of
heterobifunctional molecules, show promise in specifically targeting and eliminating cancer …

GPR52 is a highly conserved, brain-enriched, G s/olf-coupled orphan G protein-coupled
receptor (GPCR) that controls various cyclic AMP (cAMP)-dependent physiological and …

Highlights•Dysregulated PRC2 links tumor development with an EZH2 inhibitor approved in
the market.•EED is an attractive drug target associated with PRC2 potentially mitigating …

The scientific community has shown considerable interest in proteolysis-targeting chimeras
(PROTACs) in the last decade, indicating their remarkable potential as a means of achieving …

Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in
hematological malignancies that potentially circumvents many constraints of existing small …

In the past 20 years, we have seen a wave of innovative technology and novel drug
modalities that may overcome limitations of classical therapeutic approaches, such as small …

Human papillomavirus (HPV)-induced cancers still represent a major health issue for
worldwide population and lack specific therapeutic regimens. Despite substantial …